

POSITIVELY FUNDAMENTAL

LYFIX • LYFAX • LYFCX


The current market environment is...well, you know how it is. It's all anyone is talking about. Fed tightening, inflation, recession, war in Eastern Europe, bears swiping downward...not a whole lot to be positive about.

As the biotech sector recovers from the longest and deepest drawdown in its history, the AlphaCentric LifeSci Healthcare Fund (LYFIX) has been outperforming its index. How?

It's all about the fundamentals.

the fundamental need

No matter what happens in the economy, the demand for lifesaving and life-improving medical treatment is relatively inelastic. As many cyclical companies in a broad range of sectors head into the red, biotech and pharma companies seem to be "going green." And a deepening recession could most certainly intensify this trend. **Translation: the life sciences business model is intact.**



Many profitable companies are beating estimates and raising guidance in the current environment (especially biotech and pharma)

Disruptive innovators can create exceptional upside with clinical and regulatory success

Companies that release breakthrough medical data can see material stock price increases

Recapitalizing development-stage company balance sheets can generate additional alpha

reading is fundamental

A company's fundamentals matter in life sciences/healthcare. Reading the scientific and technical factors behind those fundamentals can be incredibly complex. Evaluating them properly and pointedly should require a scientific, medical, regulatory, business, and financial acumen not typically found in an individual portfolio manager.


Knowing what to own is often half the battle. The real potential for victory may also lie in knowing what to avoid. **That's our key to downside defense.**



the fundamental resource

The Fund employs an alpha-generating strategy that can work independently of the market environment. In fact, it was designed to outperform broad market exposure.

Portfolio Manager, Mark Charest, Ph.D., is a chemical biologist and co-inventor on eight drug patents (including an FDA-approved therapeutic). He identifies opportunities by targeting three, thematic, investment areas. **Herein lies the road that has led to outperformance.**



Finding a seasoned, proven, life sciences portfolio manager is important – but it's not enough. Mark Charest is *more* than a seasoned, proven portfolio manager. He's also a successful scientist.

Having access to a personal chef would be nice – but imagine hiring a personal chef who was also a nutritionist, personal trainer, and mental coach.

it's kind of like that...
fundamentally speaking.

 **AlphaCentric**

855.674.FUND

alphacentricfunds.com

info@alphacentricfunds.com

There is no guarantee that any investment strategy will achieve its objectives, generate profits, or avoid losses.

Important Risk Information

Investing in the Fund carries certain risks. The Fund will invest a percentage of its assets in derivatives, such as futures and options contracts. The use of such derivatives and the resulting high portfolio turn-over may expose the Fund to additional risks that it would not be subject to if it invested directly in the securities and commodities underlying those derivatives. The Fund may experience losses that exceed those experienced by funds that do not use futures contracts and options strategies. Investing in commodities markets may subject the Fund to greater volatility than investments in traditional securities. Currency trading risks include market risk, credit risk and country risk. Foreign investing involves risks not typically associated with U.S. investments. Changes in interest rates and the liquidity of certain investments could affect the Fund's overall performance. The Fund is non-diversified and as a result, changes in the value of a single security may have significant effect on the Fund's value.

Other risks include U.S. Government securities risks and investments in fixed income securities. Typically, a rise in interest rates causes a decline in the value of fixed income securities or derivatives owned by the Fund. Furthermore, the use of leverage can magnify the potential for gain or loss and amplify the effects of market volatility on the Fund's share price. The Fund is subject to regulatory change and tax risks; changes to current rules could increase costs associated with an investment in the Fund. These factors may affect the value of your investment.

Investors should carefully consider the investment objectives, risks, charges, and expenses of the funds before investing. The prospectus contains this and other information about the funds. Read carefully before investing. Investors may obtain a copy of the prospectus by calling 844-223-8637. Distributed by Northern Lights Distributors, LLC. (Member FINRA). 5761-NLD-08292022